Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2016

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement are shown below (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2016		2015		2014
Japan	License	$	3,465	$	1,024	$	518
	Milestones		10,000		—		—
	Total license and milestone revenue	$	13,465	$	1,024	$	518
	Collaboration services revenue*	$	166	$	198	$	356

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2016		Deferred Revenue at December 31, 2016		Total Consideration Through December 31, 2016
License	$	45,710	$	—	$	45,710
When and if available compounds		21		26		47
Manufacturing--clinical supplies		2,121		—		2,121
Committee services		20		—		20
Total license and collaboration services revenue	$	47,872	$	26	$	47,898

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2016		2015		2014
Europe	License	$	10,956	$	17,677	$	13,935
	Milestones		—		—		—
	Total license and milestone revenue	$	10,956	$	17,677	$	13,935
	Collaboration services revenue*	$	1,191	$	2,697	$	3,179

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2016		Deferred Revenue at December 31, 2016		Total Consideration Through December 31, 2016
License	$	412,272	$	—	$	412,272
When and if available compounds		376		409		785
Manufacturing--clinical supplies		9,875		—		9,875
Development services--in progress		33,032		—		33,032
Committee services		285		—		285
Total license and collaboration services revenue	$	455,840	$	409	$	456,249

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW and China Agreements were as follows (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2016		2015		2014
U.S. / RoW and China	License	$	112,931	$	114,392	$	102,738
	Milestones		—		15,000		—
	Total license and milestone revenue	$	112,931	$	129,392	$	102,738
	Collaboration services revenue*	$	40,738	$	29,731	$	16,820
	China single unit of accounting**	$	—	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW and China Agreements, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2016		Deferred Revenue at December 31, 2016		Total Consideration Through December 31, 2016
License	$	402,697	$	—	$	402,697
Co-development, information sharing & committee services		90,775		31,659		122,434
Manufacturing--clinical supplies		357		61		418
China-single unit of accounting		—		82,542		82,542
Total license and collaboration services revenue	$	493,829	$	114,262	$	608,091